Vivimed Labs Limited has secured significant legal relief as the Telangana High Court granted an interim stay on all Central Bureau of Investigation proceedings following search and seizure operations conducted at the pharmaceutical company's premises. The development comes after the company approached the High Court challenging the CBI actions initiated based on a State Bank of India complaint.

CBI Search and Seizure Operations

The Central Bureau of Investigation conducted search and seizure operations at Vivimed Labs' premises on 20th January, 2026. The operations were carried out by CBI's Banking Securities Fraud Branch from Bengaluru and New Delhi based on a complaint filed by State Bank of India's IFB branch in Hyderabad.

High Court Interim Relief

Vivimed Labs approached the High Court for the State of Telangana at Hyderabad seeking relief from the CBI proceedings. On 6th February, 2026, Justice Nagesh Bheemapaka granted comprehensive interim relief to the company in Writ Petition No. 1843 of 2026.

The High Court's interim order provides significant protection to Vivimed Labs by staying all further proceedings pursuant to the search and seizure operations. The court has restrained the CBI from taking any coercive steps against the company, its directors, and other stakeholders based on the search operations conducted on 20th January, 2026.

Legal Arguments and Court's Reasoning

Senior Counsel Avinash Desai, representing Vivimed Labs, argued that the search and seizure operations were based on SBI's classification of the company's account as 'fraud'. The counsel contended that this fraud declaration had been previously suspended by the court in an earlier petition (W.P.No.24697 of 2025), making the CBI's reliance on such classification inappropriate.

The High Court accepted these arguments and noted that since the fraud declaration was under suspension, the CBI should not have proceeded with coercive actions based on that classification.

Comprehensive Stay Order

The interim stay order encompasses multiple aspects of protection for Vivimed Labs. The court has restrained the CBI from taking any coercive steps based on both the search and seizure operations and SBI's complaint or fraud declaration. This comprehensive relief covers all proceedings until further orders from the High Court.

The case is scheduled for next hearing on 6th March, 2026, when the court will further examine the matter and determine the future course of action.

Vivimed Labs Limited has announced that its Board of Directors will meet on February 13, 2026, to review and approve the company's third quarter financial results for FY26. The pharmaceutical company made this announcement in compliance with regulatory requirements, notifying both major stock exchanges about the scheduled board meeting.

Meeting Details and Agenda

The board meeting is scheduled to take place on Friday, February 13, 2026, at the company's Hyderabad office. The primary agenda includes consideration and approval of unaudited financial results covering both standalone and consolidated performance metrics.

Regulatory Compliance

The announcement was made pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements), 2015. Vivimed Labs communicated this information to both BSE Limited and National Stock Exchange of India Ltd, where the company's shares are traded under the codes BSE - 532660 and NSE - VIVIMEDLAB respectively.

Company Information

Vivimed Labs Limited operates with its registered office located at Kolhar Industrial Area, Bidar, Karnataka, while maintaining its corporate office in Hyderabad, Telangana. The company secretary Yugandhar Kopparthi signed the official communication to the stock exchanges. The meeting agenda also includes consideration of any other items that may be brought before the board during the session.

Investors and stakeholders will be awaiting the financial results that will provide insights into the company's performance for the quarter and nine months ending December 31, 2025.